The orthopedic oncology market is anticipated to see tremendous growth through 2026, according to a Future Market Insights report.
Here are five insights:
1. The market is being pushed by the rapidly aging population with increasing risk of developing cancer. Of this patient population, those with retinoblastoma or tuberous sclerosis are at a higher risk of developing soft tissue sarcoma.
2. Key market players will need to overcome the high costs associated with musculoskeletal oncology disease treatment along with the lack of awareness of treatment therapies.
3. In 2016, the American Cancer Society estimated there were nearly 3,300 new cases of bone and joint cancer. Additionally, there were 12,310 new cases of soft tissue sarcomas.
4. As treatments advance, radiofrequency ablation has become the standard and preferred choice for osteoid osteoma treatment.
5. Other minimally invasive techniques, such as kyphoplasty, vertebroplasty and acetabuloplasty, have become more common treatment methods in the orthopedics oncology market.